As MYC/BCL2 double expression strongly predicts outcomes in patients with DLBCL treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (51), we analyzed the correlation of expression of SAMHD1 with MYC and BCL2 but found no evidence of a significant correlation (P= 0.4) (Supplementary Figure S3C, D). Here, SAMHD1 is linked to diffuse large B-cell lymphoma.